Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Chugai Pharmaceutical to related companies based on the strength of its earnings, risk, valuation, analyst recommendations, institutional ownership, profitability and dividends.
Earnings and Valuation
This table compares Chugai Pharmaceutical and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Chugai Pharmaceutical | $8.41 billion | $2.91 billion | 23.18 |
| Chugai Pharmaceutical Competitors | $18.34 billion | $3.19 billion | 560.54 |
Chugai Pharmaceutical’s rivals have higher revenue and earnings than Chugai Pharmaceutical. Chugai Pharmaceutical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
0.0% of Chugai Pharmaceutical shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Dividends
Chugai Pharmaceutical pays an annual dividend of $0.24 per share and has a dividend yield of 1.1%. Chugai Pharmaceutical pays out 25.0% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.4% and pay out 48.2% of their earnings in the form of a dividend.
Profitability
This table compares Chugai Pharmaceutical and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Chugai Pharmaceutical | 35.63% | 24.91% | 20.67% |
| Chugai Pharmaceutical Competitors | -2,391.71% | -204.89% | -14.89% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Chugai Pharmaceutical and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Chugai Pharmaceutical | 0 | 3 | 1 | 1 | 2.60 |
| Chugai Pharmaceutical Competitors | 7870 | 13817 | 25857 | 1043 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 30.33%. Given Chugai Pharmaceutical’s rivals higher probable upside, analysts plainly believe Chugai Pharmaceutical has less favorable growth aspects than its rivals.
Volatility & Risk
Chugai Pharmaceutical has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Chugai Pharmaceutical’s rivals have a beta of -0.05, indicating that their average stock price is 105% less volatile than the S&P 500.
Summary
Chugai Pharmaceutical rivals beat Chugai Pharmaceutical on 8 of the 15 factors compared.
About Chugai Pharmaceutical
Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its work focuses on areas including oncology, immunology, hematology and neuroscience, and its portfolio includes biologic and antibody-based medicines as well as other pharmaceutical products. The company was established in Japan in 1925 and is headquartered in Tokyo. Since 2002, Chugai has been part of the Roche Group through a strategic alliance, while continuing to operate as a Japan-based pharmaceutical company.
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
